The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 6.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: May 4, 2011
Expiration Date: May 4, 2014
Now in its sixth year, this two‐day symposium has been planned for the providers of care to patients with rheumatic diseases. Given the wide variety of rheumatologic disorders, and an ever‐increasing number of diagnostic procedures and treatment options, it is necessary to provide clinicians with information about strategies for the early diagnosis of these conditions, novel state‐of‐the‐art diagnostic tools, and opportunities to utilize the most effective treatments to ensure optimal patient outcomes.
This activity is intended for rheumatologists, internists, gerontologists, orthopedic surgeons, nurses, nurse practitioners, and other allied health professionals.
After attending this activity, the participant will demonstrate the ability to:
- Recognize the major dermatologic manifestations of the rheumatic diseases
- Identify how to diagnose and manage osteoarthritis related shoulder, foot, and ankle disorders
- Appraise current management approaches and controversies in the diagnosis and treatment of lyme disease
- Discuss new treatment strategies in SLE
- Introduce quantitative scores by patients and physicians into usual rheumatology care
- Discuss diagnosis and treatment of common musculoskeletal presentations of lyme disease
Notice About Off-Label Use Presentations
The Johns Hopkins University School of Medicine/ Sixth Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases (EM) may include presentations on drugs or devices, or use of drugs or devices, which have not been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. The Johns Hopkins University School of Medicine is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations on off-label uses, does not imply an endorsement by Johns Hopkins of the uses, products, or techniques presented.
All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.
Instructions to obtain a CME Certificate for this activity
To obtain CME Credits for this activity, you must register online at http://www.hopkinscme.edu/CourseDetail.aspx/80024519 . After you have registered and paid the $35 registration fee, please follow the steps given on the website to complete your post-test.
A Certificate of Credits will be given upon passing the post-test with a score of at least 70% or better. Registrations will not be accepted after May 4, 2014.
Policy on Speaker and Provider Disclosure
It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.
Full Disclosure Policy Affecting CME Activities
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of The Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:
|John Campbell, MD||Grants/Research Support: Synthes
Speaker Bureau: Biomet; Orthohelix
|Robin Gawlik, RN||Grants/Research Support: Roche
Honorarium: Genentech; UCB
|Gerald Lazarus, MD||Grants/Research Support: HealthPoint Woundcare|
|Timothy McAlindon, MD, MPH, MRCP||Grants/Research Support: NIH; NIAMS; Cephalon Inc.;
Gelita‐AG; Genetench; Human Genome Sciences; Stryker;
Biotech; Source MDX
Consultant: Nicox; Gelita
Stock Shareholder: Source MDX
Honorarium: GSK; Stryker; Biotech
Patent Royalties: US Patent for conducting clinical trials
(no income anticipated)
|Rosalind Ramsey‐Goldman, MD, DrPH||Grants/Research Support: Human Genomes Science;
Aspreva; Genentech; Bristol‐Myers Squibb
Consultant: Human Genomes Science
Other Financial or Material Support: Bristol‐Myers Squibb
All other speakers have indicated that they have not received financial support for consultation, research or evaluation or have a financial interest relevant to their presentation.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:
|Rosalind Ramsey‐Goldman, MD, DrPH||Only three medications (aspirin, corticosteroids,
hydroxychloroquine) are FDA approved medications for
SLE. All other medications are considered off‐label use.
All other speakers have indicated that they will not reference unlabeled/unapproved uses of drugs or products.
Lecture Titles and Objectives
Diagnosing and Managing Steroid Withdrawal Syndrome: An Endocrinologist’s Perspective
Objective: To evaluate steroid induced adrenal insufficiency and how to taper steroids after long-term use.
Objective: To discuss diagnosis and treatment of common musculoskeletal presentations of lyme disease.
Myositis: Recent Updates
Objectives: To review, in a cased-based format, the various forms of autoimmune myopathies ; To discuss the latest discoveries as they relate to autoimmune myopathies.
Objective: To review the biologic basis for therapeutic interventions in osteoarthritis.
Patient Questionnaires as Standard Office Practice: Why and How
Objective: To introduce quantitative scores by patients and physicians into usual rheumatology care.
Rheumatoid Arthritis of the Foot & Ankle
Objectives: To identify patterns of disease involvement; To discuss contemporary surgical and non-surgical options for treatment of rheumatoid involvement of the foot and ankle.
SLE Treatment Update
Objective: To discuss new treatment strategies in SLE.
When Skin Breaks Down: Fudnamentals of Wound Healing for the Rheumatologist
Objective: To diagnose and treat common causes of leg ulcers in rheumatological patients.
Nursing Considerations in Rheumatology Medications – Basics to Biologics
Objective: To identify the medications used in treatment of rheumatoid arthritis and discuss side effects and appropriate nursing management.